Direct and indirect costs of rheumatoid arthritis and related conditions in France: a 2015–2023 nation-wide population-based study
Authors' conclusion
The economic burden of RA in France has grown substantially, with a shift toward higher medication and indirect costs.
Study context
- Population
- Patients with rheumatoid arthritis (RA) or related conditions in France, 2015–2023, identified in the SNDS (nearly the entire French population)334,290 patients in 2023
- Outcome
- Evolution of direct and indirect costs of RA and related conditions (annual reimbursed expenditures)
- Follow-up
- 2015–2023
Methodological detailsnation-wide, National Health Data System (SNDS), validated algorithms
- Nation-wide
- National Health Data System (SNDS)
- Validated algorithms
Main finding
As reported in the abstract
Annual costs of RA, 2015 to 2023
- Number of patients with RA, 2015 to 2023 (+26%)
- 265,270 to 334,290
- Total reimbursed expenditures
- €885.9 million to €1118.3 million
- Mean cost per patient per year (stable), 2023
- €3345
- Medication costs, 2015 to 2023 (+39%)
- €404.3 million to €563.9 million
- Indirect costs: second largest component from 2020 onward; increase over study period
- +48%
Observational data: associations, not effects.
Original publication
Direct and indirect costs of rheumatoid arthritis and related conditions in France: a 2015–2023 nation-wide population-based study. Joint Bone Spine. Published 11 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →